These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 32497036)

  • 21. Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome.
    Auer K; Bachmayr-Heyda A; Aust S; Sukhbaatar N; Reiner AT; Grimm C; Horvat R; Zeillinger R; Pils D
    Oncotarget; 2015 Jul; 6(19):17261-75. PubMed ID: 25991672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
    Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
    Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.
    Lawson BC; Yang RK; Euscher ED; Ramalingam P; Malpica A
    Hum Pathol; 2021 Sep; 115():76-83. PubMed ID: 34153306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma.
    Chui MH; Doodnauth SA; Erdmann N; Tiedemann RE; Sircoulomb F; Drapkin R; Shaw P; Rottapel R
    Cancer Res; 2019 Nov; 79(21):5536-5549. PubMed ID: 31530568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.
    Zhai Y; Wu R; Kuick R; Sessine MS; Schulman S; Green M; Fearon ER; Cho KR
    J Pathol; 2017 Sep; 243(1):16-25. PubMed ID: 28608929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired chemotherapy resistance in ovarian cancer.
    Christie EL; Bowtell DDL
    Ann Oncol; 2017 Nov; 28(suppl_8):viii13-viii15. PubMed ID: 29232469
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
    Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas.
    Soong TR; Howitt BE; Miron A; Horowitz NS; Campbell F; Feltmate CM; Muto MG; Berkowitz RS; Nucci MR; Xian W; Crum CP
    J Pathol; 2018 Nov; 246(3):344-351. PubMed ID: 30043522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma.
    Soong TR; Howitt BE; Horowitz N; Nucci MR; Crum CP
    Gynecol Oncol; 2019 Feb; 152(2):426-433. PubMed ID: 30503267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
    Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
    Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
    Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
    [No Abstract]   [Full Text] [Related]  

  • 32. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphatase and Tensin Homolog Is a Potential Target for Ovarian Cancer Sensitization to Cytotoxic Agents.
    McCormick A; Earp E; Leeson C; Dixon M; O'Donnell R; Kaufmann A; Edmondson RJ
    Int J Gynecol Cancer; 2016 May; 26(4):632-9. PubMed ID: 26905328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model.
    Huang D; Gaul DA; Nan H; Kim J; Fernández FM
    J Proteome Res; 2019 Aug; 18(8):3184-3194. PubMed ID: 31290664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.
    Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K
    Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.
    Kreuzinger C; von der Decken I; Wolf A; Gamperl M; Koller J; Karacs J; Pfaffinger S; Bartl T; Reinthaller A; Grimm C; Singer CF; Braicu EI; Cunnea P; Gourley C; Smeets D; Boeckx B; Lambrechts D; Perco P; Horvat R; Berns EMJJ; Cacsire Castillo-Tong D
    Cancer Lett; 2019 Sep; 459():1-12. PubMed ID: 31150822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
    Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
    Yan S; Xuan J; Brajanovski N; Tancock MRC; Madhamshettiwar PB; Simpson KJ; Ellis S; Kang J; Cullinane C; Sheppard KE; Hannan KM; Hannan RD; Sanij E; Pearson RB; Chan KT
    Br J Cancer; 2021 Feb; 124(3):616-627. PubMed ID: 33173151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
    Ohsuga T; Yamaguchi K; Kido A; Murakami R; Abiko K; Hamanishi J; Kondoh E; Baba T; Konishi I; Matsumura N
    BMC Cancer; 2017 Aug; 17(1):580. PubMed ID: 28851311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
    Ghannam-Shahbari D; Jacob E; Kakun RR; Wasserman T; Korsensky L; Sternfeld O; Kagan J; Bublik DR; Aviel-Ronen S; Levanon K; Sabo E; Larisch S; Oren M; Hershkovitz D; Perets R
    Oncogene; 2018 Apr; 37(17):2213-2224. PubMed ID: 29379162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.